A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs FPA 144 (Primary)
  • Indications Bladder cancer; Gastric cancer; Lymphoma; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Five Prime Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to a Five Prime Therapeutics media release, the company has opened an additional cohort in this trial test FPA144 as a treatment for bladder cancer patients whose tumors overexpress FGFR2b, as assessed by the company's IHC test. The company is adding sites that specialize in bladder cancer to support enrollment in this cohort.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results assessing antitumor activity and safety of FPA144 in patients with FGFR2b+ gastric cancer enrolled in parts 1 and 2 of the study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top